ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02199392
Recruitment Status : Completed
First Posted : July 24, 2014
Last Update Posted : February 16, 2015
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
The purpose of this single-dose, open-label, sequential, three-period study in 15 healthy subjects was to assess the influence of P-glycoprotein inhibition and simultaneous CYP3A4 and P-glycoprotein induction on lenvatinib pharmacokinetics following single dose oral administration of 24 mg lenvatinib to healthy volunteers.

Condition or disease Intervention/treatment Phase
P-glycoprotein Healthy Volunteers Drug: Lenvatinib Phase 1

Detailed Description:
This is a single-dose, open-label, sequential, three-period study in 15 healthy subjects to assess the influence of P-glycoprotein inhibition and simultaneous CYP3A4 and P-glycoprotein induction on lenvantinib pharmacokinetics following single dose oral administration of 24 mg lenvatinib to healthy volunteers. The study will consist of two phases: Pretreatment and Treatment. The Pretreatment Phase will have two periods: Screening and Baseline 1. The purpose of the Screening Period is to obtain informed consent and to establish protocol eligibility. The purpose of the Baseline 1 is to confirm protocol eligibility. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. The purpose of Baselines 2 and 3 are to confirm continued protocol eligibility. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Lenvatinib

Arm Intervention/treatment
Experimental: Lenvatinib 24 mg
The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
Drug: Lenvatinib
subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
Other Name: E7080




Primary Outcome Measures :
  1. Pharmacokinetics of lenvatinib: Cmax [ Time Frame: Predose and up to 168 hours post dose ]
  2. Pharmacokinetics of lenvatinib: AUC(0-inf) [ Time Frame: Predose and up to 168 hours post dose ]

Secondary Outcome Measures :
  1. Pharmacokinetics of lenvatinib: AUC(0-inf) [ Time Frame: Predose and up to 168 hours post dose ]
  2. Safety as measured by all Adverse Events (AEs) [ Time Frame: Predose and up to 168 hours post dose ]
  3. Safety as measured by laboratory values [ Time Frame: Predose and up to 168 hours post dose ]
  4. Safety as measured by physical examinations [ Time Frame: Predose and up to 168 hours post dose ]
  5. Safety as measured by vital signs [ Time Frame: Predose and up to 168 hours post dose ]
  6. Safety as measured by ECGs [ Time Frame: Predose and up to 168 hours post dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

Subjects must meet all of the following criteria to be included in this study:

  1. Non-smoking (i.e., no use of nicotine or nicotine containing products within the past 3 months), male or female subjects, age greater than or equal to 18 years and lesser than or equal to 55 years
  2. Body mass index (BMI) greater than or equal to 18 and lesser than or equal to 30 kg/m2 at Screening
  3. Females may not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
  4. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
  5. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, a nonhormonal-based intrauterine device, a doublebarrier method [such as condom plus diaphragm with spermicide], or have a vasectomised partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. Use of hormonal contraceptives (e.g., oral contraceptive, contraceptive implant, hormone-releasing IUD) as the primary method of contraception does not meet the definition of a highly effective method of birth control for this study because Rifampin is known to cause failure of hormonal contraceptives. If currently abstinent, the subject must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation
  6. Male subjects must have had a successful vasectomy (confirmed azoospermia) or they and their female partner must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed through the study period and for 30 days after study drug discontinuation
  7. Provide written informed consent
  8. Are willing and able to comply with all aspects of the protocol

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from this study:

  1. Subjects who had a clinically significant illness that required medical treatment within 8 weeks or a clinically significant infection within 4 weeks of dosing
  2. Subjects with a disease that may influence the outcome of the study; such as psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or subjects who have a congenital abnormality in metabolism within 4 weeks prior to dosing
  3. Subjects with a history of gastrointestinal surgery (hepatectomy, nephrotomy, digestive organ resection, etc.) that may affect pharmacokinetic profiles of lenvatinib or rifampin
  4. Subjects with a known history of clinically significant drug or food allergies or presently experiencing significant seasonal allergy
  5. Subjects who experienced a weight loss or gain of more than 10% between Screening and prior to dosing
  6. Subjects with any clinically abnormal symptom or organ impairment found on medical history, symptoms/signs, vital signs, ECG finding, or laboratory test results which require medical treatment
  7. Subjects with a QTc interval greater than 450 ms at Screening or Baseline
  8. Subjects with a hemoglobin level lesser than 12.0 g/dL
  9. Subjects who had a positive result from human immunodeficiency virus (HIV) or hepatitis C virus antibody (HCVAb) screening tests, or clinical evidence of active viral hepatitis A or B
  10. Subjects with a known or suspected history of drug or alcohol misuse within 6 months prior to Screening, or a positive urine drug or alcohol test at Screening or Baseline
  11. Subjects who have consumed caffeinated beverages within 72 hours prior to Baseline
  12. Subjects who have taken dietary supplements, juice, or herbal preparations or other foods or beverages that may affect various drug metabolizing enzymes and transporters [e.g., alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, mustard), and charbroiled meats] within 2 weeks prior to dosing
  13. Subjects who have taken herbal preparations containing St. John's Wort within 4 weeks prior to dosing
  14. Subjects who have taken prescription drugs within 4 weeks prior to dosing
  15. Subjects who have taken over-the-counter (OTC) medications within 2 weeks prior to dosing
  16. Subjects who have participated in another clinical trial of an investigational drug or device within 4 weeks prior to dosing
  17. Subjects who have received blood products within 4 weeks, or donated blood within 8 weeks, or donated plasma within 1 week of dosing
  18. Subjects who have engaged in heavy exercise within 2 weeks prior to dosing (e.g., marathon runners, weight lifters, etc.)
  19. Subjects who have any condition that would make him/her, in the opinion of the investigator, unsuitable for the study or who, in the opinion of the investigator, are not likely to complete the study for any reason
  20. Known intolerance to the study drugs or any of the excipients
  21. Females who are either pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02199392


Locations
United States, Washington
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
Eisai Inc.

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT02199392     History of Changes
Other Study ID Numbers: E7080-A001-007
First Posted: July 24, 2014    Key Record Dates
Last Update Posted: February 16, 2015
Last Verified: January 2015

Keywords provided by Eisai Inc.:
P-glycoprotein
Healthy Volunteers

Additional relevant MeSH terms:
Rifampin
Krestin
Lenvatinib
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Antineoplastic Agents
Protein Kinase Inhibitors
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Antiviral Agents
Interferon Inducers
Radiation-Protective Agents
Protective Agents